cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.6084/m9.figshare.30043457
title: Preterm birth rates and risk factors among women with cervical incompetence undergoing prophylactic cerclage: a systematic review and meta-analysis

description: Preterm birth is the leading cause of neonatal mortality and long-term health complications. Cervical cerclage (CC) represents a critical intervention for extending pregnancy duration and enhancing neonatal survival in patients diagnosed with cervical insufficiency. The aim of this study was to identify risk factors for preterm birth through a meta-analysis comparing outcomes between preterm and full-term deliveries following non-emergency CC. PubMed, EMBASE, Cochrane Library, Web of Science (WOS), and Scopus were searched to identify studies fulfilling predefined inclusion and exclusion criteria on 31 March 2025. The primary outcome measure was the preterm birth rate, which was calculated as the proportion of preterm birth cases in the total sample size. The impact of various risk factors on preterm birth was further analysed. A total of 45 studies were included, and the meta-analysis revealed that the aggregate preterm birth rate at 37 weeks was approximately 48.09% following CC. Compared with twin pregnancies, singleton pregnancies were associated with a lower risk of preterm birth (odds ratio [OR]: 0.71; 95% CI: 0.55–0.91; <i>p</i> = 0.008). Among surgery-related factors, CC indicated by physical examination poses a greater risk. Short cervical length prior to CC and elevated inflammatory markers, such as C-reactive protein (CRP), were significantly associated with preterm birth (OR: 0.79; 95% CI: 0.66–0.95; <i>p</i> = 0.011). This study identified critical risk factors for preterm birth following CC, including physical examination indications, a cervical length ≤ 1.5 cm, cervical dilatation, and CRP abnormalities. These findings are instrumental in identifying high-risk individuals and guiding effective medical resource allocation. However, due to study limitations, large-scale studies with multiple PTB cut-off timepoints and comprehensive analyses of risk factors are necessary to refine preventive and therapeutic approaches for preterm birth. Preterm birth, or giving birth too early, is a leading cause of newborn death. A surgical procedure called cervical cerclage is sometimes used to help women who are at risk of giving birth too early. However, it is not always successful, and the reasons why it fails are not fully understood. This study looked at 45 previous studies to find out what increases the chance of early birth even after this treatment. Nearly half of the women still gave birth early, even after having the procedure. Women who were more likely to give birth early included those carrying twins, those with a very short cervix before treatment, those with signs of infection in the body, and those who had the procedure based on specific medical tests. These findings can help doctors identify women who are at higher risk and provide them with better care.
DOI: 10.6084/m9.figshare.30043457.v1
title: Preterm birth rates and risk factors among women with cervical incompetence undergoing prophylactic cerclage: a systematic review and meta-analysis

description: Preterm birth is the leading cause of neonatal mortality and long-term health complications. Cervical cerclage (CC) represents a critical intervention for extending pregnancy duration and enhancing neonatal survival in patients diagnosed with cervical insufficiency. The aim of this study was to identify risk factors for preterm birth through a meta-analysis comparing outcomes between preterm and full-term deliveries following non-emergency CC. PubMed, EMBASE, Cochrane Library, Web of Science (WOS), and Scopus were searched to identify studies fulfilling predefined inclusion and exclusion criteria on 31 March 2025. The primary outcome measure was the preterm birth rate, which was calculated as the proportion of preterm birth cases in the total sample size. The impact of various risk factors on preterm birth was further analysed. A total of 45 studies were included, and the meta-analysis revealed that the aggregate preterm birth rate at 37 weeks was approximately 48.09% following CC. Compared with twin pregnancies, singleton pregnancies were associated with a lower risk of preterm birth (odds ratio [OR]: 0.71; 95% CI: 0.55–0.91; <i>p</i> = 0.008). Among surgery-related factors, CC indicated by physical examination poses a greater risk. Short cervical length prior to CC and elevated inflammatory markers, such as C-reactive protein (CRP), were significantly associated with preterm birth (OR: 0.79; 95% CI: 0.66–0.95; <i>p</i> = 0.011). This study identified critical risk factors for preterm birth following CC, including physical examination indications, a cervical length ≤ 1.5 cm, cervical dilatation, and CRP abnormalities. These findings are instrumental in identifying high-risk individuals and guiding effective medical resource allocation. However, due to study limitations, large-scale studies with multiple PTB cut-off timepoints and comprehensive analyses of risk factors are necessary to refine preventive and therapeutic approaches for preterm birth. Preterm birth, or giving birth too early, is a leading cause of newborn death. A surgical procedure called cervical cerclage is sometimes used to help women who are at risk of giving birth too early. However, it is not always successful, and the reasons why it fails are not fully understood. This study looked at 45 previous studies to find out what increases the chance of early birth even after this treatment. Nearly half of the women still gave birth early, even after having the procedure. Women who were more likely to give birth early included those carrying twins, those with a very short cervix before treatment, those with signs of infection in the body, and those who had the procedure based on specific medical tests. These findings can help doctors identify women who are at higher risk and provide them with better care.
DOI: 10.48597/8nv4-ukgz
title: Measurement of HCH (hexachlorocyclohexanes) at Pallas (Matorova)

description: Measurement of HCH (hexachlorocyclohexanes) at Pallas (Matorova)
DOI: 10.48597/wywu-ekqq
title: HCH (hexachlorocyclohexanes) at Pallas (Matorova)

description: Measurement of HCH (hexachlorocyclohexanes) at Pallas (Matorova)
DOI: 10.6084/m9.figshare.28007951
title: Comparison of the efficacy of vaginal micronised progesterone tablet and gel for <i>in vitro</i> fertilisation

description: Luteal phase support (LPS) with progesterone is a generally accepted practice after controlled ovarian stimulation, although the best protocols for LPS have been debated. We aimed to compare the efficacy of vaginal micronised progesterone tablets and 8% vaginal progesterone gel for LPS using real-world data. This retrospective study included 459 <i>in vitro</i> fertilisation/intracytoplasmic sperm injection cycles performed at a university hospital from 2005 to 2019. All cycles were followed by fresh day 3 embryo transfer (ET). Either progesterone tablets or gel was used for LPS. To control the conditional probability of progesterone tablets or gel use, doubly robust inverse probability weighting composed of inverse-probability-of-treatment weighting (IPTW) and regression adjustment (RA). IPTW was performed based on the covariate balancing propensity score (CBPS). Progesterone tablets were administered in 65 cycles, and progesterone gel was administered in 394 cycles. Women who used progesterone tablets were more likely to be older (36 vs. 34 years), have primary infertility (78.5% vs. 61.4%), use gonadotropin-releasing hormone antagonist (60.0% vs. 43.2%), and have fewer retrieved oocytes (seven vs. nine) and transferred embryos (two vs. three) than participants who used progesterone gel. After IPTW-CBPS and RA analysis for the above covariates, the adjusted odds for clinical pregnancy in women who used progesterone tablets were 1.10 times compared with women who used progesterone gel; however, the 95% confidence interval did not reach statistical significance (0.96–1.26). Clinical pregnancy was comparable between vaginal micronised progesterone tablets and vaginal progesterone gel for LPS in fresh day 3 ET cycles. <i>In vitro</i> fertilisation (IVF) treatment helps couples who have difficulty getting pregnant by using special medications to stimulate the ovaries and produce more eggs. However, the use of these medications can sometimes cause a hormone called progesterone to become too low. Progesterone is very important for helping the early stages of pregnancy, so additional progesterone is usually given to support the treatment. The most common way to give progesterone during IVF is through the vagina, which is convenient and effective. In this study, we compared two different forms of vaginal progesterone: tablets and gel. The medical records of 459 IVF cycles from January 2005 to December 2019 were reviewed. Vaginal micronised progesterone tablets were used in 65 cycles, and vaginal progesterone gel was used in 394 cycles. To ensure fair results, we matched the two groups based on various factors that could affect the outcomes. Our results showed that the success rates of getting pregnant were similar between the two forms of progesterone. This suggests that both progesterone tablets and progesterone gel are equally effective options for supporting IVF treatment.
DOI: 10.6084/m9.figshare.28007951.v1
title: Comparison of the efficacy of vaginal micronised progesterone tablet and gel for <i>in vitro</i> fertilisation

description: Luteal phase support (LPS) with progesterone is a generally accepted practice after controlled ovarian stimulation, although the best protocols for LPS have been debated. We aimed to compare the efficacy of vaginal micronised progesterone tablets and 8% vaginal progesterone gel for LPS using real-world data. This retrospective study included 459 <i>in vitro</i> fertilisation/intracytoplasmic sperm injection cycles performed at a university hospital from 2005 to 2019. All cycles were followed by fresh day 3 embryo transfer (ET). Either progesterone tablets or gel was used for LPS. To control the conditional probability of progesterone tablets or gel use, doubly robust inverse probability weighting composed of inverse-probability-of-treatment weighting (IPTW) and regression adjustment (RA). IPTW was performed based on the covariate balancing propensity score (CBPS). Progesterone tablets were administered in 65 cycles, and progesterone gel was administered in 394 cycles. Women who used progesterone tablets were more likely to be older (36 vs. 34 years), have primary infertility (78.5% vs. 61.4%), use gonadotropin-releasing hormone antagonist (60.0% vs. 43.2%), and have fewer retrieved oocytes (seven vs. nine) and transferred embryos (two vs. three) than participants who used progesterone gel. After IPTW-CBPS and RA analysis for the above covariates, the adjusted odds for clinical pregnancy in women who used progesterone tablets were 1.10 times compared with women who used progesterone gel; however, the 95% confidence interval did not reach statistical significance (0.96–1.26). Clinical pregnancy was comparable between vaginal micronised progesterone tablets and vaginal progesterone gel for LPS in fresh day 3 ET cycles. <i>In vitro</i> fertilisation (IVF) treatment helps couples who have difficulty getting pregnant by using special medications to stimulate the ovaries and produce more eggs. However, the use of these medications can sometimes cause a hormone called progesterone to become too low. Progesterone is very important for helping the early stages of pregnancy, so additional progesterone is usually given to support the treatment. The most common way to give progesterone during IVF is through the vagina, which is convenient and effective. In this study, we compared two different forms of vaginal progesterone: tablets and gel. The medical records of 459 IVF cycles from January 2005 to December 2019 were reviewed. Vaginal micronised progesterone tablets were used in 65 cycles, and vaginal progesterone gel was used in 394 cycles. To ensure fair results, we matched the two groups based on various factors that could affect the outcomes. Our results showed that the success rates of getting pregnant were similar between the two forms of progesterone. This suggests that both progesterone tablets and progesterone gel are equally effective options for supporting IVF treatment.
DOI: 10.48597/d7sa-9zj2
title: Measurement of HCH (hexachlorocyclohexanes) at Pallas (Matorova)

description: Measurement of HCH (hexachlorocyclohexanes) at Pallas (Matorova)
DOI: 10.48597/g7zy-bv2j
title: Measurement of HCH (hexachlorocyclohexanes) at Pallas (Matorova)

description: Measurement of HCH (hexachlorocyclohexanes) at Pallas (Matorova)
DOI: 10.6084/m9.figshare.30061819
title: Systemic immune-inflammation index and risk of gestational diabetes and preeclampsia: a systematic review and meta-analysis

description: The systemic immune-inflammation index (SII) has been a marker and prognostic indicator of several diseases. However, its utility in pregnancy is unknown. Herein, we reviewed the evidence on the ability of SII to predict gestational diabetes mellitus (GDM) and preeclampsia (PE). A systematic search of PubMed, Embase, Scopus and Web of Science was conducted for studies comparing SII between GDM/PE and non-GDM/non-PE groups. Studies reporting diagnostic accuracy data were also included. The last date of the search was 5 November 2024. Risk of bias was assessed using Newcastle Ottawa Scale. Random-effect meta-analysis was conducted comparing values of SII between GDM/PE and non-GDM/non-PE groups. Nine studies were eligible. Four studies reported data on GDM and five on PE. Most studies measured SII in the first trimester. The pooled analysis showed no statistically significant difference in the SII values between PE and non-PE groups (MD: 13.07, 95% confidence interval (CI): −117.21, 143.35, <i>I</i><sup>2</sup> = 78%). Meta-analysis of four studies comparing data of GDM and non-GDM groups showed that SII was significantly higher in GDM females (MD: 210.32, 95% CI: 57.3, 363.34, <i>I</i><sup>2</sup> = 94%). The sensitivity of SII to predict PE varied from 40 to 77.5% while specificity varied from 53.8 to 67.5%. For studies on GDM, the sensitivity and specificity values varied from 66 to 80.2% and 34.4 to 65%, respectively. SII values are significantly higher in GDM compared to non-GDM females. However, SII values did not correlate with PE. SII may have potential in predicting GDM which needs to be explored by further studies. The systemic immune-inflammation index, a blood count-based index, has been used to predict disease occurrence and outcomes. However, its role in pregnancy remains unclear. We searched scientific literature for studies that compared SII values between pregnant women with and without gestational diabetes/preeclampsia (PE). After combining data from studies, we noted that SII values were not notably different between women with or without PE. However, it was noted that SII values was notably higher in women with gestational diabetes. To conclude, SII levels are much higher in women with GDM compared to women who do not have gestational diabetes. But SII value does not seem to be linked to PE.
DOI: 10.6084/m9.figshare.30061819.v1
title: Systemic immune-inflammation index and risk of gestational diabetes and preeclampsia: a systematic review and meta-analysis

description: The systemic immune-inflammation index (SII) has been a marker and prognostic indicator of several diseases. However, its utility in pregnancy is unknown. Herein, we reviewed the evidence on the ability of SII to predict gestational diabetes mellitus (GDM) and preeclampsia (PE). A systematic search of PubMed, Embase, Scopus and Web of Science was conducted for studies comparing SII between GDM/PE and non-GDM/non-PE groups. Studies reporting diagnostic accuracy data were also included. The last date of the search was 5 November 2024. Risk of bias was assessed using Newcastle Ottawa Scale. Random-effect meta-analysis was conducted comparing values of SII between GDM/PE and non-GDM/non-PE groups. Nine studies were eligible. Four studies reported data on GDM and five on PE. Most studies measured SII in the first trimester. The pooled analysis showed no statistically significant difference in the SII values between PE and non-PE groups (MD: 13.07, 95% confidence interval (CI): −117.21, 143.35, <i>I</i><sup>2</sup> = 78%). Meta-analysis of four studies comparing data of GDM and non-GDM groups showed that SII was significantly higher in GDM females (MD: 210.32, 95% CI: 57.3, 363.34, <i>I</i><sup>2</sup> = 94%). The sensitivity of SII to predict PE varied from 40 to 77.5% while specificity varied from 53.8 to 67.5%. For studies on GDM, the sensitivity and specificity values varied from 66 to 80.2% and 34.4 to 65%, respectively. SII values are significantly higher in GDM compared to non-GDM females. However, SII values did not correlate with PE. SII may have potential in predicting GDM which needs to be explored by further studies. The systemic immune-inflammation index, a blood count-based index, has been used to predict disease occurrence and outcomes. However, its role in pregnancy remains unclear. We searched scientific literature for studies that compared SII values between pregnant women with and without gestational diabetes/preeclampsia (PE). After combining data from studies, we noted that SII values were not notably different between women with or without PE. However, it was noted that SII values was notably higher in women with gestational diabetes. To conclude, SII levels are much higher in women with GDM compared to women who do not have gestational diabetes. But SII value does not seem to be linked to PE.
DOI: 10.48597/6bab-2jpc
title: Measurement of HCH (hexachlorocyclohexanes) at Pallas (Matorova)

description: Measurement of HCH (hexachlorocyclohexanes) at Pallas (Matorova)
DOI: 10.48597/6f59-42v4
title: Measurement of HCH (hexachlorocyclohexanes) at Pallas (Matorova)

description: Measurement of HCH (hexachlorocyclohexanes) at Pallas (Matorova)
DOI: 10.6084/m9.figshare.28103561
title: Effects of gonadotropin-releasing hormone antagonist (GnRH-ant) cessation on trigger day in a GnRH-ant protocol: a meta-analysis

description: The gonadotropin-releasing hormone antagonist (GnRH-ant) protocol is associated with few oocytes retrieved, few mature oocytes and poor endometrial receptivity. Omission of GnRH-ants on trigger day seems unlikely to induce preovulation and may improve outcomes in the GnRH-ant protocol. This study aimed to systematically evaluate the effects of GnRH-ant cessation on trigger day on in vitro fertilisation outcomes following the GnRH-ant protocol. We searched PubMed, Ovid/MEDLINE, Wanfang, VIP, CNKI and ClinicalTrials.gov databases. The last search was conducted on 10 December 2023 in English or Chinese, without time limitations on the collection of studies from the databases. The references in these articles were manually searched. Randomised controlled trials (RCTs) and cohort studies aimed at assessing the effects of GnRH-ant cessation on trigger day using the GnRH-ant protocol were included. The eligible studies included at least one of the main outcomes: number of oocytes retrieved, proportion of mature oocytes, implantation rate or clinical pregnancy rate. Three studies with 1449 cycles were included. Cessation of GnRH-ant on trigger day improved the proportion of mature oocytes (odds ratio [OR] = 1.26, 95% confidence interval [CI] = 1.09–1.45, <i>I</i><sup>2</sup> = 0%) but did not affect the number of oocytes retrieved (mean difference [MD] = 0.50, 95% CI = −0.07 to 1.07, <i>I</i><sup>2</sup> = 47%), implantation rate (OR = 0.95, 95% CI = 0.69–1.30, <i>I</i><sup>2</sup> = 0%), clinical pregnancy rate (OR = 1.06, 95% CI = 0.71–1.58, <i>I</i><sup>2</sup> = 0%), endometrial thickness (MD = −0.09, 95% CI = −0.27 to 0.10, <i>I</i><sup>2</sup> = 0%) or cycle cancellation rate (OR = 0.64, 95% CI = 0.15–2.74, I<sup>2</sup> = 0%). Cessation of GnRH-ant on trigger day of the GnRH-ant protocol is suggested because it could improve the proportion of mature oocytes. However, further RCTs are required. The gonadotropin-releasing hormone antagonist (GnRH-ant) protocol is widely used to treat patients undergoing in vitro fertilisation. However, this protocol is associated with fewer oocytes retrieved, fewer mature oocytes and poorer endometrial receptivity than the depot gonadotropin-releasing hormone agonist protocol. The omission of GnRH-ants on trigger day seems unlikely to induce preovulation and may improve outcomes in the GnRH-ant protocol. This meta-analysis was performed to systematically evaluate the effects of cessation of GnRH-ants on trigger day in in vitro fertilisation outcomes following the GnRH-ant protocol. The cessation of GnRH-ants on trigger day improved the proportion of mature oocytes. It does not compromise the number of oocytes retrieved, implantation rate, clinical pregnancy rate or induction of preovulation. GnRH-ants should be omitted on trigger day of the GnRH-ant protocol during controlled ovarian hyperstimulation.